A double-blind, randomised, placebo-controlled trial to study the anti-tumour effects of 250 mg FASLODEX (fulvestrant) in oestrogen receptor-positive primary breast cancers in premenopausal women

Study identifier:9238IL/0041

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A double-blind, randomised, placebo-controlled trial to study the anti-tumour effects of 250 mg FASLODEX (fulvestrant) in oestrogen receptor-positive primary breast cancers in premenopausal women

Medical condition

Breast Cancer

Phase

Phase 2

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Jan 1971

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2181&filename=CSR-9238IL-0041.pdf
Download
CSR-9238IL-0041.pdf
Download
Trial Results Summaries
Available here

A double-blind, randomised, placebo-controlled trial to study the anti-tumour effects of 250 mg FASLODEX (fulvestrant) in oestrogen receptor-positive primary breast cancers in premenopausal women

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2181&filename=CSR-9238IL-0041.pdf

CSR-9238IL-0041.pdf

Trial Results Summaries